Evidence map›Paper›PMID 41849003›Full record

ArticlePain and therapy2026

Real-World Safety and Effectiveness of Mirogabalin in Chinese Adults with Diabetic Peripheral Neuropathic Pain: a Protocol of ReMIssion Study.

Lin Zhao, Botao Liu, Hong Chen, Bin Lu, Weimin Wang, Yiqian Shi, Min Li, Na Guo, Bifa Fan, Xiaoying Li

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pain and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06812117 (A Prospective, Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06812117 active not recruitingnot on this map

A Prospective, Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Mirogabalin in Chinese Adult Patients With Diabetic Peripheral Neuropathic Pain (DPNP) in Real-world Clinical Practice Setting (ReMIssion Study)

TypeobservationalSponsorDaiichi SankyoRan2025 to 2026Enrolled721ConditionsDiabetic Peripheral Neuropathic PainArmsNo Drug
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lin Zhao *Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Botao Liu *Department of Pain Management, China-Japan Friendship Hospital, Beijing, 100029, China.
Hong Chen *Department of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Bin LuDepartment of Endocrinology and Metabolism, Huadong Hospital, Fudan University, Shanghai, 200040, China.
Weimin WangDepartment of Endocrinology, Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing, 210008, China.
Yiqian ShiMedical Department, Daiichi Sankyo (China) Holdings Co., Ltd., Shanghai, 200040, China.
Min LiMedical Department, Daiichi Sankyo (China) Holdings Co., Ltd., Shanghai, 200040, China.
Na GuoMedical Department, Daiichi Sankyo (China) Holdings Co., Ltd., Shanghai, 200040, China.
Bifa FanDepartment of Pain Management, China-Japan Friendship Hospital, Beijing, 100029, China. fbf1616@yeah.net.
Xiaoying LiDepartment of Endocrinology and Metabolism, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. li.xiaoying@zs-hospital.sh.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMirogabalin is an oral Ca

methodsThe ReMIssion study is a multicenter, prospective, observational study that aims to enroll 720 patients from around 36 centers. The study population will consist of patients aged ≥ 18 years, who are treatment-naïve, and have a visual analog scale (VAS) score of ≥ 40 mm. Patients will be observed for 15 weeks, including 14 weeks of mirogabalin treatment and a 1-week follow-up. PLANNED OUTCOMES: The primary endpoint is to evaluate the real-world safety of mirogabalin, whereas the secondary endpoint is to evaluate the real-world effectiveness of mirogabalin in Chinese patients with DPNP. Exploratory endpoints will investigate the real-world usage pattern and patient-reported outcomes (PRO) associated with mirogabalin treatment in Chinese adult patients with DPNP. In China, this is the first observational study focusing on the safety and effectiveness of mirogabalin in real-world clinical practice. Mirogabalin may offer clinical benefits for DPNP management, including improved real-world effectiveness, tolerable safety, and favorable usage patterns, potentially enhancing patient-reported outcomes.

trial registrationClinicaltrial.gov/NCT06812117.

Indexed as

Chinese adult patientsDiabetic peripheral neuropathic painMirogabalinReal-worldReMIssion study

Identifiers

PMID41849003
PMCPMC13172212

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.